A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The overall objective is to evaluate the efficacy, tolerability, and safety of a single dose
of RBT-9 versus placebo in coronavirus disease 2019 (COVID-19) infection in non-critically
ill adults who are at high risk of progression.
Phase:
Phase 2
Details
Lead Sponsor:
Renibus Therapeutics, Inc. Renibus Therapuetics, Inc.